Jun 2026 (Q2 FY26) — Aug 5, 2026
Sarepta Q2 FY26 — Strong Financials & Pipeline Progress Amidst ELEVIDYS Adoption Focus
Read the full callSarepta (SRPT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Sarepta earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 401 | −34.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.3 | −15.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.9 | −102.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$17.73 +3.68% · +$0.63
Performance −21.2% 1Y
1Y: $22.51 on 17 Oct 2025 → $17.73. High $24.45 (3 Nov 2025), low $14.86 (31 Jul 2026).
- Previous close
- $17.1
- 52-week range
- $14.86 – $24.45
- One year
- −23.08%
Overview
- Symbol
- SRPT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Sarepta earnings calls (SRPT)
Financials
What the filings say
Net profit, year on year: −102% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 467 | 658 | 745 | 611 | 399 | 443 | 731 | 401 |
| Expenses | 445 | 497 | 1,045 | 496 | 503 | 855 | 372 | 388 |
| Operating profit | 22 | 162 | -300 | 116 | -103 | -412 | 358 | 13 |
| Operating margin | 4.8% | 24.6% | −40.3% | 18.9% | −25.9% | −92.9% | 49.0% | 3.3% |
| Other income | 12 | 10 | -83 | 38 | -91 | 133 | -15 | -15 |
| Interest | 5 | -32 | -5 | -5 | 2 | — | -22 | -22 |
| Profit before tax | 34 | 172 | -384 | 154 | -194 | -278 | 343 | -2 |
| Tax rate | 1.2% | 7.4% | −16.7% | −28.1% | 7.3% | −1.6% | 3.6% | −179.6% |
| Net profit | 34 | 159 | -448 | 197 | -51 | -412 | 331 | -5 |
| EPS ($ per share) | 0.35 | 1.65 | -4.60 | 2.01 | -0.50 | -3.93 | 3.15 | -0.05 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,579 | -2,294 | -2,848 | -3,207 | -3,910 | -4,446 | -4,211 | -4,877 |
| Total liabilities | 610 | 1,005 | 2,223 | 2,220 | 2,743 | 2,405 | 2,435 | 2,209 |
| Fixed assets | 97 | 130 | 190 | 191 | 180 | 227 | 340 | 345 |
| Investments | 803 | 290 | 436 | 0 | 1,023 | 1,248 | 252 | 138 |
| Total assets | 1,642 | 1,823 | 2,985 | 3,148 | 3,128 | 3,265 | 3,963 | 3,350 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -389 | -456 | 107 | -443 | -325 | -501 | -206 | -205 |
| Cash from investing | -370 | 287 | -122 | 495 | -1,047 | -166 | 756 | 70 |
| Cash from financing | 530 | 643 | 682 | 562 | 233 | 125 | 125 | -168 |
| Net cash flow | -229 | 473 | 668 | 614 | -1,140 | -542 | 675 | -304 |
| Capital expenditure | -61 | -60 | -82 | -38 | -31 | -76 | -137 | -102 |
| Free cash flow | -450 | -516 | 25 | -482 | -356 | -577 | -343 | -307 |
Insider filings
50 filings between Nov 17, 2025 and Sep 4, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$417.4K
2 sales by 2 insiders
Compensation
not trading decisions- 14
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
- 28
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Estepan Ian Michael | — | $294.2K | Dec 16, 2025 |
| Mayo Stephen | — | $123.2K | Mar 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 22,025 | $489.4K |
| Sep 4, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 24,799 | $551.0K |
| Sep 4, 2026 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 13,272 | $294.9K |
| Sep 4, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 21,423 | $476.0K |
| Jul 28, 2026 | SEVERINO MICHAEL Chief Executive Officer | Award | 756,104 | — |
| Jun 4, 2026 | Wigzell Hans Lennart Rudolf Director | Award | 16,875 | — |
| Jun 4, 2026 | Chambers Michael Andrew Director | Award | 16,875 | — |
| Jun 4, 2026 | BEHRENS M KATHLEEN Director | Award | 16,875 | — |
| Jun 4, 2026 | Nicaise Claude Director | Award | 16,875 | — |
| Jun 4, 2026 | Connelly Deirdre P Director | Award | 16,875 | — |
| Jun 4, 2026 | Barry Richard Director | Award | 16,875 | — |
| Jun 4, 2026 | Boor Kathryn Jean Director | Award | 16,875 | — |
| Jun 4, 2026 | Mayo Stephen Director | Award | 16,875 | — |
| Mar 12, 2026 | Mayo Stephen Director | Sale | 7,239 | $123.2K |
| Mar 11, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 1,097 | $18.7K |
| Mar 11, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 948 | $16.1K |
| Mar 11, 2026 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 256 | $4.4K |
| Mar 11, 2026 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 974 | $16.6K |
| Mar 9, 2026 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 346 | $5.9K |
| Mar 9, 2026 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 162 | $2.7K |
| Mar 9, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 583 | $9.9K |
| Mar 9, 2026 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 113 | $1.9K |
| Mar 9, 2026 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 484 | $8.2K |
| Mar 9, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 895 | $15.2K |
| Mar 9, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 1,036 | $17.6K |
| Mar 9, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 504 | $8.5K |
| Mar 2, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 875 | $14.2K |
| Mar 2, 2026 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 450 | $7.3K |
| Mar 2, 2026 | Estepan Ian Michael Chief Operating Officer | Tax withheld | 3,301 | $53.5K |
| Mar 2, 2026 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 408 | $6.6K |
| Mar 2, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 767 | $12.4K |
| Mar 2, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 3,718 | $60.2K |
| Mar 1, 2026 | Estepan Ian Michael Chief Operating Officer | Option exercise | 8,125 | — |
| Mar 1, 2026 | Rodino-Klapac Louise President, R&D and Tech Ops | Option exercise | 8,125 | — |
| Feb 26, 2026 | Estepan Ian Michael Chief Operating Officer | Option exercise | 5,381 | $73.8K |
| Feb 26, 2026 | Estepan Ian Michael Chief Operating Officer | Option exercise | 2,069 | $28.4K |
| Jan 29, 2026 | Nicaise Claude Director | Option exercise | 10,500 | $144.0K |
| Jan 29, 2026 | Nicaise Claude Director | Tax withheld | 6,780 | $143.9K |
| Jan 27, 2026 | BEHRENS M KATHLEEN Director | Tax withheld | 6,494 | $144.0K |
| Jan 27, 2026 | BEHRENS M KATHLEEN Director | Option exercise | 10,500 | $144.0K |
| Dec 16, 2025 | Estepan Ian Michael Chief Operating Officer | Sale | 13,187 | $294.2K |
| Dec 7, 2025 | INGRAM DOUGLAS S Chief Executive Officer | Award | 50,000 | $0 |
| Dec 7, 2025 | INGRAM DOUGLAS S Chief Executive Officer | Award | 269,542 | $0 |
| Dec 7, 2025 | INGRAM DOUGLAS S Chief Executive Officer | Award | 96,541 | $0 |
| Dec 7, 2025 | INGRAM DOUGLAS S Chief Executive Officer | Award | 73,001 | $0 |
| Dec 7, 2025 | INGRAM DOUGLAS S Chief Executive Officer | Award | 50,000 | $0 |
| Dec 1, 2025 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 78 | $1.6K |
| Dec 1, 2025 | Wong Ryan Ho-Yan Chief Financial Officer | Tax withheld | 80 | $1.7K |
| Nov 28, 2025 | Rothfuss Cristin EVP, General Counsel | Tax withheld | 229 | $4.8K |
| Nov 17, 2025 | Rodino-Klapac Louise President, R&D and Tech Ops | Tax withheld | 4,582 | $84.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Sarepta Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Sarepta Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading